Time: 2024-05-17
Jonathan An, an assistant professor of oral sciences at the University of Washington, found himself unintentionally involved in the fervor surrounding anti-aging through his research on mice with periodontal disease. An's experiments with rapamycin-infused chow for mice showed promising results in delaying symptoms of the disease and regrowing tooth-supporting jaw bones. Now, An is planning to test rapamycin in humans to potentially offer a drug that enhances dental health. As the longevity field takes notice of rapamycin's success in extending the lifespan of various species, including mice, wealthy lifehackers and biotech investors are eager to explore the potential of this drug for life extension.Amidst the hype, experts like Matt Kaeberlein and Richard A. Miller emphasize the gradual progress in longevity research. While the field has expanded with studies on various drugs and interventions, funding limitations and narrow focus may hinder the discovery of new pathways for future therapies. Despite the slow pace, clinical trials are being conducted on longevity drugs, and researchers are optimistic about potential interventions that could enhance human healthspan.
Longevity enthusiasts envision a future where innovative treatments like rapamycin and canagliflozin could revolutionize health outcomes and lead to longer, healthier lives. However, the field remains cautious, acknowledging the complexities of human biology and the challenges of translating lab findings to human applications. As research inches forward, the goal shifts from immortality to improving overall health and well-being through scientific advancements.
Business
